Todd Christopher Longsworth, General Counsel at NovoCure Ltd (NVCR), sold 310,480 shares at $86.85 ($27.3M) on 2019-09-03, disclosed to the SEC on 2019-09-05.
Open-market sale of $27.3M NVCR by General Counsel. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $86.85 | 22,264 | $1.9M | 7.1% |
| 2 | $86.85 | 22,264 | $1.9M | 7.1% |
| 3 | $86.86 | 11,426 | $992K | 3.6% |
| 4 | $86.86 | 11,426 | $992K | 3.6% |
| 5 | $86.88 | 4,238 | $368K | 1.4% |
| 6 | $86.88 | 4,238 |
| $368K |
| 1.4% |
| 7 | $86.95 | 20,891 | $1.8M | 6.7% |
| 8 | $86.95 | 20,891 | $1.8M | 6.7% |
| 9 | $88.17 | 28,340 | $2.5M | 9.2% |
| 10 | $88.17 | 28,340 | $2.5M | 9.2% |
| 11 | $88.18 | 14,888 | $1.3M | 4.8% |
| 12 | $88.18 | 14,888 | $1.3M | 4.8% |
| 13 | $88.19 | 6,065 | $535K | 2.0% |
| 14 | $88.19 | 6,065 | $535K | 2.0% |
| 15 | $88.22 | 24,083 | $2.1M | 7.8% |
| 16 | $88.22 | 24,083 | $2.1M | 7.8% |
| 17 | $88.82 | 6,616 | $588K | 2.2% |
| 18 | $88.82 | 6,616 | $588K | 2.2% |
| 19 | $88.86 | 2,900 | $258K | 0.9% |
| 20 | $88.94 | 929 | $83K | 0.3% |
| 21 | $88.94 | 929 | $83K | 0.3% |
| 22 | $88.97 | 7,869 | $700K | 2.6% |
| 23 | $88.97 | 7,869 | $700K | 2.6% |
| 24 | $89.86 | 1,200 | $108K | 0.4% |
| 25 | $89.87 | 4,031 | $362K | 1.3% |
| 26 | $89.87 | 4,031 | $362K | 1.3% |
| 27 | $89.89 | 2,300 | $207K | 0.8% |
| 28 | $89.97 | 400 | $36K | 0.1% |
| 29 | $89.97 | 400 | $36K | 0.1% |
| Total | $87.84 avg | 310,480 | $27.3M | 100% |
| Filing → |
| NVCR | SELL | 2021-03-10 | $629K | — | Filing → |
| NVCR | SELL | 2021-03-08 | $848K | — | Filing → |
| NVCR | SELL | 2021-03-04 | $716K | — | Filing → |